GLP-1 Contraindications: Which Conditions Can Rule Out Treatment?

30 min read

Share

A pale blue felt injector pen with its cap on.

TL;DR

GLP-1 contraindications depend on the exact medication, formulation, and current prescribing information. For many commonly used products, key formal barriers include a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or a previous serious allergic reaction to the drug or its ingredients.

Pregnancy, pancreatitis, gastroparesis, kidney disease, gallstones, and diabetic eye disease may make treatment unsuitable or require closer review. However, they are not universal class-wide contraindications. At Temi, we recommend checking the current label, full medical history, and complete medication list before treatment starts or changes.

Who cannot take a GLP-1 medication? The short answer

Who cannot take a GLP-1 medication? The short answerMany GLP-1 safety summaries combine contraindications, warnings, precautions, and side effects. The resulting list may sound alarming without answering the central question: does a particular condition prohibit treatment, or does it simply call for further review?

The first rule is straightforward. Each medication has its own prescribing information. A contraindication listed for one product should not automatically be assigned to every GLP-1 medication.

For many widely used products, formal contraindications commonly include:

  • A personal or family history of medullary thyroid carcinoma, or MTC
  • Multiple Endocrine Neoplasia syndrome type 2, or MEN 2
  • A previous serious hypersensitivity reaction to the active ingredient or another product ingredient

That pattern is not identical across every medication or formulation. Exenatide products, for example, illustrate why clinicians must check the exact product rather than relying on a class-level summary.

Other health issues need more precise language. Pregnancy, severe gastrointestinal disease, previous pancreatitis, kidney disease, gallstones, and diabetic retinopathy can affect whether treatment is appropriate. They do not form one universal list that rules out every GLP-1 medication.

We use four categories when reviewing a potential prescription:

  1. Contraindicated: The current prescribing information says the product should not be used in that situation.
  2. Not recommended or should be avoided: The label or available clinical guidance advises against use, even if the issue is not in the formal contraindications section.
  3. Needs added review: The clinician may need records, tests, monitoring, a treatment adjustment, or specialist input.
  4. Common side effect: The symptom is a known adverse effect, not an automatic barrier to treatment.

The distinction has practical consequences. Mild nausea may call for a slower dose increase. Anaphylaxis after taking the same active ingredient can make reuse dangerous.

Contraindication versus warning versus side effect

A contraindication is a specific instruction in the product’s prescribing information. It identifies a situation in which the medication should not be used because the potential risk is considered unacceptable.

A warning or precaution identifies a serious concern that requires action. Depending on the risk, a clinician might avoid treatment, order tests, adjust another medication, monitor symptoms, or select a different drug.

Common side effects are different again. Nausea, constipation, diarrhea, vomiting, abdominal discomfort, and reduced appetite are often associated with GLP-1 treatment. These symptoms can become severe, but appearing on a side-effect list does not make them contraindications.

Context matters. Mild nausea after an early dose is not equivalent to repeated vomiting in someone with diagnosed gastroparesis. Temporary redness around an injection site is not the same as tongue swelling, widespread hives, and difficulty breathing.

Patients comparing symptoms can review our guide to the side effects of Zepbound, which covers common reactions and signs that need urgent care.

Why the answer depends on the exact prescription

Before we assess risk, we confirm four basic facts:

  • The active ingredient
  • The brand, manufacturer, or dispensing pharmacy
  • The formulation and current dose
  • The reason the medication is being prescribed

Products can share an active ingredient while having different brand names, approved uses, dosing instructions, and label language. A serious reaction to an active ingredient remains relevant even if the next prescription uses another brand.

Tirzepatide also needs accurate identification. It acts on both GIP and GLP-1 receptors. Although it is commonly discussed alongside GLP-1 receptor agonists, its safety review must follow the prescribing information for the specific tirzepatide product.

The route and formulation matter as well. An approved injection, an approved oral tablet, and an online product advertised as a “tirzepatide pill” should not be treated as interchangeable. Our review of tirzepatide pills and their FDA status explains why the dosage form, source, and named ingredient need to be verified.

GLP-1 contraindications by drug and FDA label

The table below separates commonly listed formal contraindications from issues that often appear under warnings, precautions, limitations, or clinical monitoring. It is a starting point, not a substitute for current prescribing information.

Labels can change. A clinician or pharmacist should confirm the latest version for the exact brand, formulation, and market before making a treatment decision.

Active ingredientExample brandsCommon usesContraindications commonly listed for relevant productsOther major review points
Semaglutide injectionOzempicType 2 diabetes and certain risk-reduction uses in eligible adultsPersonal or family history of MTC; MEN 2; serious hypersensitivity to semaglutide or product ingredientsPancreatitis symptoms, diabetic retinopathy, severe gastrointestinal symptoms, dehydration, kidney problems, pregnancy, and hypoglycemia with some diabetes drugs
Semaglutide injectionWegovyChronic weight management and certain risk-reduction uses in eligible adultsPersonal or family history of MTC; MEN 2; serious hypersensitivity to semaglutide or product ingredientsPregnancy, severe gastrointestinal symptoms, pancreatitis, gallbladder disease, dehydration, and duplicate semaglutide or GLP-1 treatment
Semaglutide tabletRybelsusType 2 diabetesPersonal or family history of MTC; MEN 2; serious hypersensitivity to semaglutide or product ingredientsAdministration requirements, pregnancy planning, pancreatitis, eye disease, dehydration, kidney problems, and duplicate semaglutide treatment
TirzepatideMounjaroType 2 diabetesPersonal or family history of MTC; MEN 2; serious hypersensitivity to tirzepatide or product ingredientsSevere gastrointestinal disease, pancreatitis symptoms, gallbladder disease, pregnancy, oral contraceptive use, and hypoglycemia with certain diabetes medicines
TirzepatideZepboundChronic weight management and certain other uses in eligible adultsPersonal or family history of MTC; MEN 2; serious hypersensitivity to tirzepatide or product ingredientsPregnancy, severe gastrointestinal disease, pancreatitis, gallbladder disease, dehydration, oral contraceptive use, and duplicate incretin treatment
LiraglutideVictozaType 2 diabetes and certain risk-reduction uses in eligible adultsPersonal or family history of MTC; MEN 2; serious hypersensitivity to liraglutide or product ingredientsPancreatitis, gallbladder disease, dehydration, kidney problems, and hypoglycemia with certain diabetes medicines
LiraglutideSaxendaChronic weight managementPersonal or family history of MTC; MEN 2; serious hypersensitivity to liraglutide or product ingredientsPregnancy, pancreatitis, gallbladder disease, dehydration, heart-rate concerns, and duplicate liraglutide or GLP-1 treatment
DulaglutideTrulicityType 2 diabetes and certain risk-reduction uses in eligible adultsPersonal or family history of MTC; MEN 2; serious hypersensitivity to dulaglutide or product ingredientsSevere gastrointestinal disease, pancreatitis, diabetic eye disease, dehydration, kidney problems, and hypoglycemia with certain diabetes medicines
Exenatide, immediate releaseByettaType 2 diabetesSerious hypersensitivity to exenatide or product ingredients; certain previous immune reactions attributed to exenatideKidney function, pancreatitis, severe gastrointestinal disease, and the effect of delayed stomach emptying on other medicines
Exenatide, extended releaseBydureon BCiseType 2 diabetesPersonal or family history of MTC; MEN 2; serious hypersensitivity; certain previous immune reactions attributed to exenatideKidney function, pancreatitis, severe gastrointestinal disease, injection-site reactions, and gallbladder disease

A brand name alone may not answer every safety question. We also need to know whether the patient has an FDA-approved product, a compounded preparation, or a product obtained outside a licensed pharmacy.

Semaglutide and tirzepatide

Semaglutide products carrying the thyroid tumor warning are contraindicated for people with a personal or family history of MTC or MEN 2. A previous serious hypersensitivity reaction to semaglutide or the relevant product ingredients is another major barrier.

That does not make every semaglutide label identical. Products used for type 2 diabetes can have different approved uses and instructions from products used for chronic weight management.

The same principle applies to tirzepatide. Its diabetes and weight-management brands contain the same active ingredient, but clinicians still need to review the label for the product being prescribed.

Important review points outside the formal contraindications section may include:

  • Pregnancy or plans to become pregnant
  • Severe gastroparesis or other serious gastrointestinal symptoms
  • Previous pancreatitis or current symptoms suggesting pancreatitis
  • Gallbladder disease
  • Diabetic retinopathy
  • Kidney injury risk during vomiting or diarrhea
  • Concurrent insulin or sulfonylurea treatment
  • Duplicate semaglutide, tirzepatide, GLP-1, or incretin therapy

The reason for treatment also changes the stopping plan. Someone using a medication solely for weight management has different needs from a patient relying on several drugs to control diabetes. If treatment must stop, the diabetes prescriber may need to replace or adjust it.

Liraglutide and dulaglutide

Liraglutide is available under different brand names for different uses. Relevant labels generally identify MTC, MEN 2, and serious hypersensitivity as contraindications.

Dulaglutide follows a similar broad pattern. Its safety information also addresses concerns such as pancreatitis, severe gastrointestinal disease, dehydration-related kidney injury, and hypoglycemia when used with some other diabetes drugs.

A warning should not be dismissed because it falls outside the contraindications section. Severe vomiting in a patient with impaired kidney function can be dangerous. The label category helps organize the risk, but it does not replace clinical judgment.

Exenatide products

Immediate-release and extended-release exenatide products do not have identical prescribing information. We should not copy every contraindication from one formulation to another.

Some exenatide labeling also addresses a rare immune-mediated reaction involving a severe fall in platelets. If a clinician has attributed that reaction to exenatide, restarting the drug may be contraindicated under the applicable label.

A history of “low platelets” does not establish the cause. The clinician may need hospital records, hematology notes, laboratory trends, and details about when the platelet count changed relative to treatment.

This is a recurring theme in GLP-1 prescribing: a broad medical-history answer may flag a concern, but the underlying records determine what that concern means.

Which thyroid conditions rule out a GLP-1?

Which thyroid conditions rule out a GLP-1?The thyroid contraindication is specific. For products carrying it, the named concerns are medullary thyroid carcinoma and MEN 2.

It does not automatically include every thyroid disorder. Hypothyroidism, hyperthyroidism, Hashimoto’s disease, Graves’ disease, abnormal thyroid-stimulating hormone results, goiter, and most thyroid nodules are separate diagnoses.

The boxed warning associated with several products is based partly on thyroid C-cell tumors observed in animal studies. The relevance of those findings to humans is not fully established. We should not claim either that the human risk is proven or that it has been ruled out.

Clear language prevents two mistakes. People with routine thyroid disease should not assume they are automatically disqualified. At the same time, a vague or unknown family history of thyroid cancer should not be ignored.

Personal or family history of medullary thyroid carcinoma

MTC develops from thyroid C cells. It is different from papillary and follicular thyroid cancers, which arise from other thyroid cells.

During an intake, we may ask whether the patient or a close biological relative has had medullary thyroid carcinoma. The precise family-history question should follow the current label and the clinician’s process.

If someone reports that a relative had “thyroid cancer,” that description is not specific enough to determine whether the contraindication applies. Helpful records include:

  • A thyroid pathology report
  • An operative report
  • An oncology or endocrinology note
  • A genetic testing result
  • A reliable medical record naming the cancer type

A pathology report often provides the clearest answer because it can distinguish medullary cancer from papillary, follicular, anaplastic, and other thyroid cancers.

A clinician may pause prescribing until the diagnosis is confirmed. That pause does not mean the patient or relative had MTC. It means the missing detail could change whether treatment is allowed under the product label.

MEN 2 and genetic records

MEN 2 is an inherited tumor syndrome associated with a high risk of MTC and other endocrine tumors. It is often linked to pathogenic changes in the RET gene.

Some patients know only that several relatives had thyroid surgery or “gland tumors.” That history calls for follow-up questions, not a self-diagnosis based on an online checklist.

Records that may help include:

  • A RET genetic test result
  • A genetic counseling report
  • An endocrinology note
  • Documentation of a family member’s MEN 2 diagnosis
  • Thyroid pathology
  • Records concerning related endocrine tumors

A genetic result needs context. The clinician may need to know who was tested, which variant was assessed, and how the result was interpreted. A report reviewed by a genetics professional is more useful than a patient’s memory of being told that a test was “negative.”

Thyroid problems that are not automatically disqualifying

Thyroid historyAutomatic contraindication?Usual next step
HypothyroidismNoConfirm the diagnosis, treatment, and follow-up
Hashimoto’s diseaseNoReview thyroid medication and recent results when relevant
Graves’ disease or hyperthyroidismNoReview current control, symptoms, and treatment
Thyroid noduleNoReview imaging, biopsy results, and the specialist’s plan
GoiterNoConfirm the cause and ask about swallowing or airway symptoms
Papillary thyroid cancerNot the named MTC contraindicationVerify pathology and review the oncology history
Follicular thyroid cancerNot the named MTC contraindicationVerify pathology and review the oncology history
Medullary thyroid carcinomaGenerally yes for products carrying this contraindicationDo not use the affected product
Unknown thyroid cancer typeCannot be decided from the description aloneObtain pathology or specialist records

Treated hypothyroidism by itself does not match the named MTC or MEN 2 contraindications. We still recommend confirming that “thyroid disease” is not being used as a vague description of a previous cancer or hereditary syndrome.

Likewise, papillary thyroid cancer is not MTC. A history of any thyroid cancer deserves review, but clinicians should verify the actual type rather than treating all thyroid cancers as interchangeable.

Does an allergic reaction rule out one drug or the whole class?

Not every unpleasant reaction is an allergy. Nausea, diarrhea, constipation, reduced appetite, vomiting, and routine injection-site discomfort are adverse effects. On their own, they do not establish hypersensitivity.

Serious hypersensitivity can include anaphylaxis or angioedema. Possible signs include difficulty breathing, airway swelling, widespread hives with symptoms elsewhere in the body, a major blood-pressure drop, or collapse.

A serious reaction can prohibit reuse of the same drug or another brand containing the same active ingredient. For example, a serious reaction attributed to semaglutide matters when reviewing any product that contains semaglutide.

A reaction to one active ingredient does not automatically prove an allergy to the entire GLP-1 class. Even so, switching without clinical review is unsafe. A clinician may recommend allergy assessment, additional caution, or avoidance of related drugs.

The active ingredient is not the only possible trigger. A review may consider:

  • Inactive ingredients
  • Preservatives
  • Added vitamins or other substances
  • Pen, syringe, or needle materials
  • Adhesives or skin-cleaning products
  • Ingredients unique to a compounded preparation

Compounded injections may differ from approved products in concentration, inactive ingredients, packaging, and instructions. That makes the dispensing label and pharmacy record especially important.

Facts to record after a reaction

After a suspected allergic reaction, we recommend recording:

  • The active ingredient
  • The brand or pharmacy shown on the label
  • The dose and concentration
  • The lot number, if available
  • The date and time of the dose
  • The time from administration to symptom onset
  • Every symptom that occurred
  • Photos of a rash or swelling, if they can be taken safely
  • Any medication or emergency treatment received
  • The name of the emergency department or hospital
  • Whether epinephrine was used

Keep the package, pen, vial, and pharmacy label when possible. Do not use another dose to test whether the reaction happens again.

An emergency department record or allergy evaluation may help distinguish anaphylaxis from fainting, panic symptoms, a local skin reaction, or a known drug side effect. The distinction can change whether the same ingredient or related medications are considered in the future.

When the reaction needs emergency care

Call emergency services for symptoms such as:

  • Trouble breathing
  • Throat, tongue, or facial swelling
  • Collapse or loss of consciousness
  • Severe wheezing
  • Widespread hives accompanied by dizziness, vomiting, or breathing problems
  • Signs of shock, including severe confusion or cold, clammy skin

Do not wait for a portal message or routine telehealth response. A severe allergic reaction can worsen quickly and requires emergency assessment.

Mild injection-site redness can usually be discussed with the prescribing clinician. It still deserves prompt attention if it spreads, becomes painful, recurs after each dose, or appears with symptoms elsewhere in the body.

Pregnancy, breastfeeding, and plans to become pregnant

Weight-loss treatment is generally not continued during pregnancy. Relevant product labeling advises stopping weight-management medications when pregnancy is recognized.

That does not mean pregnancy appears in the formal contraindications section of every GLP-1 label. A medication can be inappropriate during pregnancy without the label classifying pregnancy under “Contraindications.”

The action matters more than the heading: stop weight-loss use as directed by the product information and contact the prescriber promptly.

Pregnancy planning also needs a product-specific timeline. Some GLP-1 medications remain in the body for an extended period after the final dose. Semaglutide labeling, for example, includes an advance stopping period before a planned pregnancy. That instruction should not be copied to every other drug without checking its current label.

Tirzepatide has an additional concern because delayed stomach emptying can affect the absorption of oral hormonal contraceptives. Its prescribing information includes specific contraceptive advice when treatment begins and when the dose increases. Patients should follow the current label and their clinician’s instructions rather than relying on a class-wide rule.

We recommend discussing pregnancy plans before the first prescription and again before any dose increase or medication change.

If pregnancy occurs during treatment

Someone using a GLP-1 or dual incretin medication for weight management should stop treatment as directed and contact the prescriber promptly once pregnancy is recognized. The clinician can confirm the exact product instructions and document the exposure.

Patients with diabetes need an additional plan. Stopping a glucose-lowering medicine without replacing or adjusting it can lead to high blood glucose. Poor glucose control during pregnancy also carries risks.

Do not borrow someone else’s insulin regimen or restart an old medication without instructions. Contact the diabetes or obstetric team for an appropriate glucose-management plan.

Repeated vomiting, dehydration, severe abdominal pain, confusion, high glucose, or ketones may require urgent assessment. These symptoms should not automatically be dismissed as pregnancy-related nausea.

If pregnancy is planned

A preconception review should start with the active ingredient and current prescribing information. It may cover:

  • The anticipated conception date
  • The timing of the last dose
  • How long the drug may remain in the body
  • Ongoing diabetes treatment
  • Contraception during the stopping period
  • Preconception care
  • Other medications that may need to change

Different drugs and formulations have different dosing intervals and clearance times. A daily injection and a long-acting weekly injection should not be assigned the same stopping schedule without evidence.

The clinician may also involve an obstetrician, endocrinologist, or primary care professional, especially when the patient has diabetes or another condition requiring continuous treatment.

Breastfeeding review

Breastfeeding advice is product-specific and may change as evidence develops. A clinical review can consider:

  • The infant’s age
  • Prematurity or other medical concerns
  • Whether the infant depends fully on breast milk
  • The parent’s reason for treatment
  • The active ingredient and formulation
  • Available information about transfer into human milk
  • Potential effects on maternal nutrition or milk supply
  • Reasonable alternatives

A lack of human data does not prove that a drug is safe. It also does not establish that harm will occur. The clinician should use the current product information and balance the potential infant exposure against the parent’s treatment needs.

Compounded products can add uncertainty because their concentrations, inactive ingredients, or added substances may differ from approved products.

Pancreatitis, gastroparesis, gallstones, and bowel symptoms

A previous episode of pancreatitis is not a universal formal contraindication across every GLP-1 medication. It still requires careful review.

The clinician may ask about the cause, severity, recurrence, alcohol use, triglycerides, gallstones, procedures, and present symptoms. These details help confirm the original diagnosis and determine whether an unresolved risk remains.

Gastroparesis is a separate concern. GLP-1 drugs delay gastric emptying as part of their mechanism. Some products are not recommended for people with severe gastroparesis or other serious gastrointestinal disease.

Severe gastroparesis is not the same as mild nausea after starting treatment. It may involve repeated vomiting, retained food, malnutrition, dehydration, unstable glucose, or hospital treatment.

Gallstones and previous gallbladder surgery do not create one automatic class-wide ban. A clinician should still review previous inflammation, pancreatitis, procedures, and any continuing pain.

Claims about bowel obstruction also need careful wording. Patients should respond to concerning symptoms and applicable label warnings, but we should not present an uncertain causal relationship as settled.

Past pancreatitis

A useful pancreatitis history answers questions such as:

  • Was the diagnosis confirmed in a hospital?
  • Were pancreatic enzymes elevated?
  • Did imaging support the diagnosis?
  • Was a likely cause identified?
  • Were gallstones present?
  • Was alcohol considered a factor?
  • Were triglycerides markedly elevated?
  • Was intensive care or surgery required?
  • Has pancreatitis happened more than once?
  • Was the suspected cause corrected?

Consider someone who previously had pancreatitis associated with gallstones and later underwent gallbladder surgery. That history does not automatically create a class-wide contraindication. The clinician may review the discharge summary, imaging, procedure records, recurrence history, and current symptoms.

A clinician may still pause or decline treatment. Formal contraindications are not the only basis for a safe prescribing decision. Recurrent pancreatitis with no clear cause or unexplained current abdominal pain may make treatment unsuitable.

Severe or persistent abdominal pain requires urgent assessment, particularly when it radiates toward the back or occurs with vomiting. The patient should seek instructions before taking another dose.

Slow stomach emptying and severe bowel symptoms

Someone with severe gastroparesis may report:

  • Vomiting food eaten much earlier
  • Feeling full after only a small amount of food
  • Unintended weight loss caused by poor intake
  • Dehydration
  • Unstable glucose readings
  • Feeding-tube use
  • Repeated emergency visits
  • A previous abnormal gastric-emptying test

The clinician may request the gastric-emptying study, gastroenterology records, endoscopy results, nutrition notes, and a current medication list. Opioids and certain other medicines can also slow gastrointestinal movement.

Mild nausea after a dose increase is different. Depending on the patient and product, it may improve with smaller meals, slower eating, hydration, or a delayed dose increase under clinician guidance.

Repeated vomiting is not a routine symptom to push through. It can contribute to dehydration, electrolyte changes, kidney injury, and poor absorption of other medications.

Severe abdominal swelling, intense pain, persistent vomiting, or an inability to pass stool or gas needs prompt medical assessment. Symptoms alone cannot identify the cause.

Gallstones and prior gallbladder surgery

Useful records for a gallbladder review may include:

  • An ultrasound or CT report
  • An emergency department or hospital note
  • A history of gallbladder inflammation
  • A history of pancreatitis
  • The date and details of gallbladder surgery
  • Records of any bile duct procedure
  • Recent liver tests obtained because of symptoms

Gallbladder removal does not eliminate every possible bile duct problem. New symptoms should not be dismissed solely because surgery occurred in the past.

Right upper abdominal pain accompanied by fever, yellow skin or eyes, pale stool, or dark urine needs prompt assessment. These symptoms may arise from gallbladder, bile duct, liver, or pancreatic disease.

Kidney disease and diabetic eye disease: monitoring, not one automatic ban

Kidney disease is not a universal GLP-1 contraindication. Even so, kidney function can influence the choice of medication, dosing, and monitoring. Some products have specific kidney-related limitations, and exenatide products require particular attention to renal status.

There is also an indirect risk. Vomiting and diarrhea can cause dehydration, reducing blood flow to the kidneys and potentially causing or worsening acute kidney injury.

Normal previous kidney function does not eliminate that possibility. Someone with chronic kidney disease may have less reserve and need earlier testing or treatment when fluid loss occurs.

Diabetic eye disease raises a different issue. A rapid improvement in glucose can temporarily worsen diabetic retinopathy in some people who already have the condition. Relevant semaglutide labeling includes monitoring language for patients with a history of diabetic retinopathy.

That diabetes-specific concern should not be copied without context to everyone taking a GLP-1 medication for weight management. A person without diabetes does not have diabetic retinopathy.

Kidney records and sick-day review

A kidney review may include:

  • A recent creatinine result
  • Estimated glomerular filtration rate, or eGFR
  • Any previous acute kidney injury
  • Dialysis status
  • Changes in urine output
  • Nephrology records
  • Diuretic use
  • Blood pressure medications
  • Recent vomiting or diarrhea
  • The ability to keep fluids down

The date of each result matters. An old laboratory result may not answer the current prescribing question, particularly after an illness, medication change, or episode of dehydration.

Contact a clinician if vomiting or diarrhea makes it difficult to keep fluids down. Same-day advice may be needed when urine output falls, dizziness develops, or symptoms continue.

Severe weakness, confusion, fainting, minimal urine output, or an inability to retain fluids can require urgent care. We do not recommend continuing to dose through severe dehydration without clinical instructions.

Diabetic retinopathy and vision changes

Patients with diabetes should tell the prescribing clinician about:

  • Known diabetic retinopathy
  • Previous retinal laser treatment
  • Eye injections
  • Retinal surgery
  • Bleeding inside the eye
  • The date of the last dilated eye examination
  • Major recent glucose or A1C changes
  • Current vision symptoms

The diabetes clinician and eye specialist may need to coordinate when glucose is expected to improve quickly. Monitoring does not necessarily mean the medication is prohibited.

Sudden vision loss needs urgent assessment. A curtain-like shadow, flashing lights accompanied by many new floaters, or a sharp decline in vision also requires prompt evaluation.

Not every vision problem is caused by diabetic retinopathy. Glucose shifts, dehydration, migraine, retinal detachment, bleeding, and other conditions can affect sight. An examination is safer than guessing at the cause.

Type 1 diabetes, ketoacidosis, insulin, and duplicate incretin therapy

A medication can be unapproved for a particular use without being formally contraindicated. These are separate regulatory concepts.

GLP-1 drugs do not replace insulin in type 1 diabetes, and they do not treat diabetic ketoacidosis, or DKA.

Patients who use insulin should not stop it simply because appetite decreases or glucose readings improve. An unsafe insulin reduction can lead to severe hyperglycemia and ketone production.

Insulin and sulfonylureas can also increase the risk of hypoglycemia when combined with a GLP-1 medication. The diabetes prescriber may need to adjust doses using glucose readings, food intake, and previous low-glucose events.

Duplicate therapy creates another avoidable risk. Depending on the product, prescribing information may advise against combination with:

  • Another product containing the same active ingredient
  • Another GLP-1 receptor agonist
  • Another incretin medication
  • A compounded copy being used at the same time
  • Samples supplied by a different clinic

Keeping all medications in one place can help the prescribing team identify active prescriptions before a refill or dose change.

Type 1 diabetes and diabetic ketoacidosis

Do not stop insulin unless the diabetes prescriber provides a clear replacement or adjustment plan. This remains true when a weight-management medication reduces food intake.

Possible DKA symptoms include:

  • Vomiting
  • Abdominal pain
  • Deep or rapid breathing
  • Severe thirst
  • Frequent urination
  • Fruity-smelling breath
  • Confusion
  • High glucose
  • Elevated ketones

In some situations, DKA can occur without the degree of high glucose a patient expects. Symptoms and ketone results therefore matter.

High ketones, deep breathing, confusion, repeated vomiting, or an inability to keep fluids down require urgent assessment. A routine GLP-1 side-effect message is not an adequate response to possible DKA.

Insulin and sulfonylureas

Before prescribing, a clinician may review:

  • Basal and mealtime insulin doses
  • Continuous glucose monitor reports
  • Finger-stick glucose records
  • Overnight low-glucose events
  • Severe lows that required another person’s help
  • Use of a sulfonylurea
  • Meal patterns
  • Kidney function

Hypoglycemia can cause shaking, sweating, hunger, weakness, confusion, seizures, or loss of consciousness. Severe events need immediate treatment under the patient’s emergency plan.

The need to adjust insulin or a sulfonylurea is a medication-management issue, not usually a blanket contraindication to every GLP-1 drug.

Patients should have a clear low-glucose plan. It should explain when to use fast-acting glucose, when to recheck, and when another person should provide emergency help.

Duplicate GLP-1 and incretin treatment

Brand names can conceal duplicate active ingredients. Ozempic, Wegovy, and Rybelsus contain semaglutide. Mounjaro and Zepbound contain tirzepatide.

A complete medication list should include:

  • Current prescriptions
  • Recently discontinued prescriptions that may still be at home
  • Free samples
  • Compounded injections
  • Oral semaglutide
  • Weight-management medicines from another clinic
  • Diabetes medicines
  • Products purchased online
  • Over-the-counter drugs and supplements

Do not alternate brands or combine leftover pens without instructions. Products may have different strengths, devices, dosing schedules, and approved uses.

Overlapping prescriptions from separate clinics are a reason to pause. The care teams need to confirm which product is active, when the previous product stopped, and whether any doses overlapped.

What a telehealth clinician may ask for before prescribing

Telehealth does not mean automatic approval. A remote clinician still needs to assess contraindications, warnings, interactions, and missing information.

A core intake may cover:

  • The diagnosis and reason for treatment
  • Height and weight
  • A complete medication list
  • Drug allergies and previous reactions
  • Pregnancy, breastfeeding, and conception plans
  • Diabetes type and treatment
  • Personal and family thyroid cancer history
  • MEN 2 history
  • Previous pancreatitis
  • Gallstones and gallbladder surgery
  • Severe nausea, vomiting, or gastroparesis
  • Kidney function
  • Diabetic eye disease
  • Prescriptions from other weight-management services

At Temi, we view a prescription pause as a clinical decision, not a failed form. The clinician may need records, laboratory work, an in-person examination, or specialist input before deciding whether treatment is appropriate.

FDA approval also requires careful wording. The FDA approves specific drug products for defined indications. It does not approve an entire telehealth membership or weight-management program.

Compounded drugs are not FDA-approved. They do not undergo the same premarket review as approved products for safety, effectiveness, quality, and labeling.

Records that can resolve a prescribing question

Helpful records include:

  • Thyroid pathology reports
  • RET genetic test results
  • Genetic counseling reports
  • Hospital discharge summaries
  • Pancreatitis imaging and laboratory results
  • Gallbladder ultrasound reports
  • Allergy or emergency department notes
  • Gastric-emptying studies
  • Recent creatinine and eGFR results
  • Diabetic eye records
  • A current medication and pharmacy list

Patients may not have these files at home. They can still provide the facility name, clinician, approximate date, and reason for the visit. Those details help the care team request the correct record.

A short note saying “thyroid cancer” may not answer the prescribing question. A pathology report identifying papillary thyroid carcinoma means something different from a report identifying medullary thyroid carcinoma.

FDA-approved products versus compounded versions

Approval applies to a particular drug product, dosage form, manufacturer, and use. It does not automatically extend to a compounded preparation containing a similar ingredient.

For a compounded prescription, we recommend confirming:

  • The named active ingredient
  • The form of that ingredient
  • The concentration
  • The dose in milligrams
  • The volume in milliliters
  • Syringe units, if applicable
  • Any added ingredients
  • The dispensing pharmacy
  • The prescriber
  • Storage instructions
  • The beyond-use date

“Units” alone do not define a medication dose. The same syringe marking can represent different milligram amounts when concentrations differ.

Added ingredients or alternative forms of an ingredient may not match the approved product. A vial labeled “semaglutide” or “tirzepatide” should not automatically be assumed to have the same formulation, instructions, or quality controls as an approved pen.

Our compounded tirzepatide safety and refill guide explains these distinctions in more detail.

Why a clinician may pause the prescription

Common reasons for a pause include:

  • A relative’s thyroid cancer type is unknown
  • The patient is actively vomiting
  • Pregnancy is possible
  • Kidney results are unavailable or outdated
  • Two incretin medications appear on the medication list
  • A reported allergy lacks enough detail
  • Severe abdominal pain has not been assessed
  • The product concentration or dose cannot be confirmed
  • The diabetes type is unclear
  • Insulin use was omitted from the initial intake

A pause does not guarantee later approval. It means the clinician does not yet have enough information to make a safe decision.

An in-person assessment may be necessary for abdominal tenderness, dehydration, thyroid findings, or acute illness. Telehealth has limits. A video visit cannot replace laboratory tests, imaging, a physical examination, or emergency care when those services are needed.

When to stop a dose, seek urgent care, or ask a clinician

The right response depends on symptom severity, the medication, and the patient’s medical history. The table below provides broad triage guidance. An individual clinician may give stricter instructions.

LevelExamplesAction
Emergency care nowTrouble breathing; face, tongue, or throat swelling; collapse; severe confusion; signs of anaphylaxis; possible DKA; severe hypoglycemia that does not respond to the treatment plan; sudden major vision lossCall emergency services or go to an emergency department
Same-day clinical adviceSevere or persistent abdominal pain; repeated vomiting; inability to keep fluids down; reduced urine; jaundice; fever with right upper abdominal pain; many new floaters; a spreading rashSeek same-day advice and ask whether further doses should be held
Routine follow-upMild nausea; manageable constipation; brief diarrhea; reduced appetite; mild injection-site redness without symptoms elsewhereTrack symptoms and discuss dosing, diet, hydration, and titration with the clinician

Long-acting medications can remain in the body after the final dose. Side effects may therefore continue after treatment is held, depending on the active ingredient, dose, and individual clearance.

Stopping a dose does not guarantee that symptoms will stop immediately. Persistent or worsening symptoms still require assessment.

After a serious event, do not restart, increase, double, or replace a dose without instructions. Do not switch to another brand without a medication review.

Emergency symptoms after a GLP-1 dose

Call emergency services for:

  • Trouble breathing
  • Swelling of the face, tongue, or throat
  • Collapse
  • Severe confusion
  • Signs of shock
  • Severe low glucose that does not improve with the prescribed treatment plan
  • Possible DKA accompanied by elevated ketones or impaired awareness

Seek urgent assessment for severe abdominal pain, persistent vomiting, inability to keep fluids down, jaundice, or a marked reduction in urine output.

A severe reaction should be documented before another prescription is considered. When practical, bring the drug package, pen or vial, medication list, and glucose records.

What are the different types of GLP-1 shot medications?

Injectable medications are best grouped by active ingredient and approved use. They are not interchangeable.

  • Semaglutide: Available under brands used for type 2 diabetes or chronic weight management
  • Liraglutide: Available under separate diabetes and weight-management brands
  • Dulaglutide: Used for type 2 diabetes and certain related risk-reduction purposes in eligible adults
  • Exenatide: Available in different formulations for type 2 diabetes
  • Tirzepatide: Available under separate brands for type 2 diabetes and chronic weight management

Tirzepatide acts at both GIP and GLP-1 receptors. It is commonly grouped with GLP-1 medications in everyday discussion, but it should still be identified as a dual agonist.

Product selection depends on the diagnosis, contraindications, kidney function, other diabetes medications, pregnancy plans, coverage, availability, and current prescribing information.

What are the new guidelines for semaglutide injections?

There is no single document called the “new guidelines” that replaces current product labeling. The right source depends on the specific question.

A current review should consider:

  • The latest prescribing information for the exact brand
  • Current FDA safety communications
  • Dated guidance from relevant medical organizations
  • The patient’s diagnosis and other medications
  • Any changes to approved uses or warnings
  • Current pregnancy and breastfeeding language

Online summaries can become outdated when labels change. Both the publication date and the label revision date matter.

Dose increases should follow the prescribed schedule. Patients should not accelerate titration because side effects are absent or because the first doses have not produced the result they expected.

Is a weight-loss program FDA-approved?

The FDA does not approve a telehealth membership or care program as a whole. It approves specific drugs, medical devices, and indications.

A program may prescribe an FDA-approved medication when clinically appropriate. That does not make the program itself “FDA-approved.”

The reverse is also true. Receiving a compounded drug through a clinician or telehealth service does not make the compounded preparation FDA-approved. We recommend asking for the exact ingredient, concentration, dose, pharmacy, and regulatory status.

FAQ

Who cannot take GLP-1 medications?

The answer depends on the exact product. Many labels prohibit use after a serious hypersensitivity reaction and in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Pregnancy, severe gastroparesis, previous pancreatitis, kidney disease, and gallbladder disease may require avoidance or additional review rather than acting as universal contraindications.

Is a telehealth weight-loss program FDA-approved?

No telehealth weight-loss program is FDA-approved as a whole. FDA approval applies to specific drugs, devices, and uses. A program may prescribe an approved medication, but the approval does not extend to the membership or service. A compounded medication supplied through a program is not FDA-approved.

What guidance should patients follow for semaglutide injections?

Patients should follow the current prescribing information for the exact semaglutide brand, the prescribed titration schedule, current FDA safety communications, and individual clinical advice. Pregnancy plans, diabetic eye disease, severe gastrointestinal symptoms, duplicate therapy, and other diabetes medicines can all affect the plan.

What types of injectable GLP-1 medications are available?

Common injectable active ingredients include semaglutide, liraglutide, dulaglutide, and exenatide. Tirzepatide is a dual GIP and GLP-1 agonist commonly discussed with them. Each product has its own approved uses, doses, contraindications, warnings, and combination limits.

Does hypothyroidism rule out semaglutide?

No. Ordinary hypothyroidism is not the same diagnosis as medullary thyroid carcinoma or MEN 2. A clinician should still confirm the thyroid history, current treatment, and any previous nodules or cancer. If a personal or family thyroid cancer type is unknown, pathology or specialist records may be needed.

Can someone use a GLP-1 after pancreatitis?

Possibly, but the decision requires individual review. Previous pancreatitis is not a universal class-wide contraindication. The clinician may assess the cause, severity, recurrence, gallstones, alcohol use, triglycerides, treatment, and current symptoms. Unresolved or recurrent disease may lead the clinician to pause or decline prescribing.

Get a GLP-1 safety review

Gather your medication list, allergy details, recent laboratory results, and relevant thyroid, pancreatic, kidney, eye, or pregnancy records. Then use Temi to request a clinician review of the exact medication, formulation, current label, and personal risks before starting or refilling treatment.

Editorial Standards

This article has not been reviewed by a licensed physician. We cite peer-reviewed studies, academic research institutions, and medical associations. Our sources are listed at the end of each article.

If you notice an error or have a concern about our content, please email supportusetemi.com.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment.

Felt Temigami re-enacting famous revolutions, from crossing the Delaware to raising a pill-bottle flag.

The revolution will be emailed.

Once a week, roughly. We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy

Temi

Start online, and a licensed physician reviews your request

See if you qualify

A licensed physician reviews every request. Nothing on this page is a prescription.